Our most significant finding was the higher prevalence of exon 4 KRAS mutations in rectal tumors compared to tumors in other colon segments (OR = 3.23, 95% CI: 1.19–8.72, p = 0.021). This evidence concerns the gene KRAS and rectal neoplasm.